The de ritis ratio: The test of time

Clinical Biochemist Reviews

Volumn 34, Issue 3, 2013, Pages 117-130

  Botros, Mona ^a   Sikaris, Kenneth A ^a  

^a MELBOURNE PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901997593     PISSN: 01598090     EISSN: 18380212     Source Type: Journal    
DOI: None     Document Type: Article

References (165)

1. De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta 1957;2:70-4.
2. Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem 1978;24:1971-9.
3. King J. Practical Clinical Enzymology. London: D. Van Nostrand Company Limited; 1965.
4. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985;5:367-75.
5. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-43.
6. Wroblewski F. The significance of alterations in transaminase activities of serum and other body fluids. Adv Clin Chem 1958;1:313-51.
7. Goldberg DM. Enzymes in the diagnosis of myocardial infarction and liver disease. Ann Clin Biochem 1971;8:195-200.
8. Goldberg DM. Clinical Enzymology. In: Ellis GP, West GB, editors. Progress in Medicinal Chemistry. Amsterdam: North Holland; 1976;13:1-158.
9. Goldberg DM, Fletcher MJ, Watts C. Serum adenosine deaminase activity in hepatic disease: a comparative enzymological evaluation. Clin Chim Acta 1966;14:720-8.
10. Schmidt E, Schmidt FW. [Methods and value of determination of glutamic acid dehydrogenase activity in the serum.A contribution to the importance of examination of enzyme relations in the serum]. Klin Wochenschr 1962;40:962-9.
11. Schmidt E, Schmidt FW. [Enzyme determinations in the serum in liver diseases.Function patterns as a means of diagnosis]. Enzymol Biol Clin (Basel) 1963;79:1-52.
12. Forster G, Filippa G, Landolt M. [The significance of glutamate dehydrogenase for the differential diagnosis of jaundices]. Helv Med Acta 1963;30:672-84.
13. Konttinen A, Härtel G, Louhija A. Multiple serum enzyme analyses in chronic alcoholics. Acta Med Scand 1970;188:257-64.
14. Aronsen KF, Hanson A, Nosslin B. The value of gamma glutamyl transpeptidase in differentiating viral hepatitis from obstructive jaundice. A statistical comparison with alkaline phosphatase. Acta Chir Scand 1965;130:92-9.
15. Aronsen KF, Nosslin B, Pihl B. The value of gammaglutamyl transpeptidase as a screen test for liver tumour. Acta Chir Scand 1970;136:17-22.
16. Betro MG, Oon RC, Edwards JB. Gamma-glutamyl transpeptidase in diseases of the liver and bone. Am J Clin Pathol 1973;60:672-8.
17. Goldberg DM, Ellis G. Mathematical and computerassisted procedures in the diagnosis of liver and biliary tract disorders. Adv Clin Chem 1978;20:49-128.
18. Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J Clin Invest 1955;34:126-31.
19. Kay HD. Plasma phosphatase: method of determination, some properties of the enzyme. J Biol Chem 1930;89:235-47.
20. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936;28:485-95.
21. Rej R. Immunochemical quantitation of isoenzymes of aspartate aminotransferase and lactate dehydrogenase. Clin Biochem 1983;16:17-9.
22. Hirano K, Matsuda K, Adachi T, Ito Y, Hayashi K, Okuno F, et al. Determination of mitochondrial aspartate aminotransferase in serum. Clin Chim Acta 1986;155:251-62.
23. Schumann G, Bonora R, Ceriotti F, Férard G, Ferrero CA, Franck PF, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees . International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 2002;40:718-24.
24. Schumann G, Bonora R, Ceriotti F, Férard G, Ferrero CA, Franck PF, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees . International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med 2002;40:725-33.
25. Yoneda K. [Aspartate aminotransferase (glutamic oxalacetic transaminase) and alanine aminotransferase (glutamic pyruvic transaminase)]. Rinsho Byori 2001;Suppl 116:72-80.
26. Kotani K, Maekawa M, Kanno T. [Reestimation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio based on JSCC consensus method-changes of criteria for a differential diagnosis of hepatic disorders following the alteration from Karmen method to JSCC method]. Nihon Shokakibyo Gakkai Zasshi 1994;91:154-61.
27. Hafkenscheid JC, Dijt CC. Determination of serum aminotransferases: activation by pyridoxal-5′-phosphate in relation to substrate concentration. Clin Chem 1979;25:55-9.
28. Jung K, Ohlrich B, Mildner D, Zubek A, Schimmelpfennig W, Egger E. The apoenzyme of aspartate aminotransferase and alanine aminotransferase in the serum of healthy persons and patients suffering from liver diseases. Clin Chim Acta 1978;90:143-9.
29. Dols JL, van Zanten AP. Clinical implications of differences between two recommended procedures for determination of aspartate aminotransferase. Clin Chem 1983;29:523-6.
30. Vanderlinde RE. Review of pyridoxal phosphate and the transaminases in liver disease. Ann Clin Lab Sci 1986;16:79-93.
31. Férard G, Imbert-Bismut F, Messous D, Piton A, Abella A, Burnat P, et al. [Influence of pyridoxal phosphate in measuring aminotransferases activities in patients with viral hepatitis]. Ann Biol Clin (Paris) 2004;62:717-20.
32. Ning M, Baker H, Leevy CM. Reduction of glutamic pyruvic transaminase in pyridoxine deficiency in liver disease. Proc Soc Exp Biol Med 1966;121:27-30.
33. Matloff DS, Selinger MJ, Kaplan MM. Hepatic transaminase activity in alcoholic liver disease. Gastroenterology 1980;78:1389-92.
34. Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5'-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86:632-6.
35. McIntyre N, Heathcote J. The laboratory in the diagnosis and management of viral hepatitis. Gastroenterology 1974;3:317-36.
36. Mastroianni A, Longoni PD, Franzini C, Facchetti G. Importance of pyridoxal-5′-phosphate addition to the assay medium for the measurement of catalytic concentrations of plasma aspartate and alanine aminotransferases in patients undergoing antineoplastic chemotherapy. Eur J Clin Chem Clin Biochem 1996;34:507-10.
37. Succari M, Ponteziere C, Meneguzzer E, Desmoulins D, Amoros-Le Fay A, Miocque M, et al. Aminotransferases in elderly people: influence of pyridoxal 5′-phosphate addition on the determination of serum aminotransferases in healthy elderly subjects. Age Ageing 1987;16:94-100.
38. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
39. Häkkinen K, Alén M. Training volume, androgen use and serum creatine kinase activity. Br J Sports Med 1989;23:188-9.
40. Koutedakis Y, Raafat A, Sharp NC, Rosmarin MN, Beard MJ, Robbins SW. Serum enzyme activities in individuals with different levels of physical fitness. J Sports Med Phys Fitness 1993;33:252-7.
41. Garcin-Webb P, Bhagat CS, Beilby JP. Plasma creatine kinase/aspartate aminotransferase ratio in the diagnosis of acute myocardial infarction. Clin Chem 1985;31:498-9.
42. Weibrecht K, Dayno M, Darling C, Bird SB. Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury. J Med Toxicol 2010;6:294-300.
43. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005;41:380-2.
44. Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkström V, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol 2008;65:253-9.
45. Helfgott SM, Karlson E, Beckman E. Misinterpretation of serum transaminase elevation in "occult" myositis. Am J Med 1993;95:447-9.
46. Price CP, Alberti KG. Biochemical assessment of liver function. In: Wright R, Alberti KGMM, Karran S, Millward-Sadler GH, editors. Liver and Biliary Disease -Pathophysiology, Diagnosis and Management. London: W.B. Saunders; 1979:381-416.
47. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis?. J Am Osteopath Assoc 2001;101:391-4.
48. Veropalumbo C, Del Giudice E, Esposito G, Maddaluno S, Ruggiero L, Vajro P. Aminotransferases and muscular diseases: a disregarded lesson. Case reports and review of the literature. J Paediatr Child Health 2012;48:886-90.
49. De Ritis F, Coltorti M, Giusti G. [Transaminase activity of human serum in viral hepatitis; preventive note]. Minerva Med 1955;46:1207-9.
50. De Ritis F, Coltorti M, Giusti G. [Transaminase activity of the blood in viral hepatitis]. Boll Soc Ital Biol Sper 1955;31:394-6.
51. De Ritis F, Coltorti M, Giusti G. [Diagnostic value and pathogenetic significance of transaminase activity changes in viral hepatitis]. Minerva Med 1956;47:167-71.
52. De Ritis F, Coltorti M, Giusti G. Serum and liver transaminase activities in experimental virus hepatitis in mice. Science 1956;124:32.
53. De Ritis F, Mallucci L, Coltorti M, Giusti G, Caldera M. Anicteric virus hepatitis in a closed environment as shown by serum transaminase activity. Bull World Health Organ 1959;20:589-602.
54. De Ritis F, Giusti G, Piccinino F, Cacciatore L. Biochemical laboratory tests in viral hepatitis and other hepatic diseases. Bull World Health Organ 1965;32:59-72.
55. Botros M, Sikaris KA, Lu ZX, McNeil A. The short term prognostic usefulness of the De Ritis ratio. Clin Biochem Rev 2013;34:S18.
56. Gitlin N. The serum glutamic oxaloacetic transaminase/ serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis. Am J Gastroenterol 1982;77:2-4.
57. Sunheimer R, Capaldo G, Kashanian F, Finck C, Woo J, Korins M, et al. Serum analyte pattern characteristic of fulminant hepatic failure. Ann Clin Lab Sci 1994;24:101-9.
58. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis; relationship to cirrhosis. Gastroenterology 1988;95:734-9.
59. Cadiot G, Ink O, Boutron A, Hanny P, Laurent-Puig P, Buffet C. Mitochondrial aspartate aminotransferase in nonalcoholic cirrhosis. Gastroenterology 1989;97:240-1.
60. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43:2156-9.
61. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-8.
62. Anderson FH, Zeng L, Rock NR, Yoshida EM. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res 2000;18:63-71.
63. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000;95:1545-50.
64. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?. J Gastroenterol Hepatol 2000;15:386-90.
65. Giannini E, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. Am J Gastroenterol 2001;96:918-9.
66. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142-6.
67. Park SY, Kang KH, Park JH, Lee JH, Cho CM, Tak WY, et al. [Clinical efficacy of AST/ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis]. Korean J Gastroenterol 2004;43:246-51.
68. Ustündag Y, Bilezikçi B, Boyacioǧlu S, Kayataş M, Odemir N. The utility of AST/ALT ratio as a noninvasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis. Nephrol Dial Transplant 2000;15:1716-7.
69. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?. Ann Clin Biochem 2005;42:441-7.
70. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al; ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012;56:55-62.
71. Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon 2012;12:177-84.
72. Stevenson M, Lloyd-Jones M, Morgan MY, Wong R. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technol Assess 2012;16:1-174.
73. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-20.
74. Stránský J, Ryzlová M, Striteský J, Horák J. [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection]. Vnitr Lek 2002;48:924-8.
75. Giannini E, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol 2002;97:2855-60.
76. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-24.
77. Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri M, Molinaro E, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700.
78. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
79. Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010;16:5710-5.
80. Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011;7:445-54.
81. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-75.
82. Nalpas B, Vassault A, Le Guillou A, Lesgourgues B, Ferry N, Lacour B, et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984;4:893-6.
83. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985;5:367-75.
84. Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, et al. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One 2012;7:e47687.
85. Harinasuta U, Chomet B, Ishak K, Zimmerman HJ. Steatonecrosis-Mallory body type. Medicine (Baltimore) 1967;46:141-62.
86. Cohen JA, Kaplan MM. The SGOT/SGPT ratio- an indicator of alcoholic liver disease. Dig Dis Sci 1979;24:835-8.
87. Correia JP, Alves PS, Camilo EA. SGOT-SGPT ratios. Dig Dis Sci 1981;26:284.
88. Alves PS, Camilo EA, Correia JP. The SGOT/ SGPT ratio in alcoholic liver disease. Acta Med Port 1981;3:255-60.
89. Salaspuro M. Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme 1987;37:87-107.
90. Takahashi A, Sekiya C, Yazaki Y, Ono M, Sato H, Hasebe C, et al. [Hepatic GOT and GPT activities in patients with various liver diseases-especially alcoholic liver disease]. Hokkaido Igaku Zasshi 1986;61:431-6.
91. Sharpe PC. Biochemical detection and monitoring of alcohol abuse and abstinence. Ann Clin Biochem 2001;38:652-64.
92. Hietala J, Puukka K, Koivisto H, Anttila P, Niemelä O. Serum gamma-glutamyl transferase in alcoholics, moderate drinkers and abstainers: effect on gt reference intervals at population level. Alcohol Alcohol 2005;40:511-4.
93. Rosman AS, Lieber CS. Diagnostic utility of laboratory tests in alcoholic liver disease. Clin Chem 1994;40:1641-51.
94. Matloff DS, Selinger MJ, Kaplan MM. Hepatic transaminase activity in alocholic liver disease. Gastroenterology 1980;78:1389-92.
95. Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5′-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86:632-6.
96. Nalpas B, Vassault A, Le Guillou A, Lesgourgues B, Ferry N, Lacour B, et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984;4:893-6.
97. Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem 1978;24:1971-9.
98. Ishii H, Okuno F, Shigeta Y, Tsuchiya M. Enhanced serum glutamic oxaloacetic transaminase activity of mitochondrial origin in chronic alcoholics. Curr Alcohol 1979;5:101-8.
99. Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology 1986;6:608-14.
100. Nalpas B, Vassault A, Le Guillou A, Lesgourgues B, Ferry N, Lacour B, et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984;4:893-6.
101. Okuno F, Ishii H, Kashiwazaki K, Takagi S, Shigeta Y, Arai M, et al. Increase in mitochondrial GOT (m-GOT) activity after chronic alcohol consumption: clinical and experimental observations. Alcohol 1988;5:49-53.
102. Hourigan KJ, Bowling FG. Alcoholic liver disease:a clinical series in an Australian private practice. J Gastroenterol Hepatol 2001;16:1138-43.
103. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39:336-9.
104. Larsson A, Tryding N. Is it necessary to order aspartate aminotransferase with alanine aminotransferase in clinical practice?. Clin Chem 2001;47:1133-5.
105. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004;39:336-9.
106. Liangpunsakul S, Qi R, Crabb DW, Witzmann F. Relationship between alcohol drinking and aspartate aminotransferase:alanine aminotransferase (AST:ALT) ratio, mean corpuscular volume (MCV), gammaglutamyl transpeptidase (GGT), and apolipoprotein A1 and B in the U.S. population. J Stud Alcohol Drugs 2010;71:249-52.
107. Yue M, Ni Q, Yu CH, Ren KM, Chen WX, Li YM. Transient elevation of hepatic enzymes in volunteers after intake of alcohol. Hepatobiliary Pancreat Dis Int 2006;5:52-5.
108. Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Rydén BO, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 1997;32:179-86.
109. Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int 2007;27:694-9.
110. Kimm H, Kim S, Jee SH. The independent effects of cigarette smoking, alcohol consumption, and serum aspartate aminotransferase on the alanine aminotransferase ratio in korean men for the risk for esophageal cancer. Yonsei Med J 2010;51:310-7.
111. Himmelstein DU, Woolhandler SJ, Adler RD. Elevated SGOT/SGPT ratio in alcoholic patients with acetaminophen hepatotoxicity. Am J Gastroenterol 1984;79:718-20.
112. Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas R. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int 2007;27:1144-7.
113. Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, et al. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2009;238:150-9.
114. Hsu YC, Tai DI. Unusually high alanine aminotransferase to aspartate aminotransferase ratio in a patient with cyproterone-induced icteric hepatitis. Chang Gung Med J 2011;34:34-8.
115. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
116. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-9.
117. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006;101:76-82.
118. Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, et al. Alcohol consumption and mortality among women. N Engl J Med 1995;332:1245-50.
119. Jackson R, Beaglehole R. Alcohol consumption guidelines: relative safety vs absolute risks and benefits. Lancet 1995;346:716.
120. Loomba R, Bettencourt R, Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment Pharmacol Ther 2009;30:1137-49.
121. Adams LA, Knuiman MW, Divitini ML, Olynyk JK. Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol 2008;23:1089-93.
122. Park EY, Lim MK, Oh JK, Cho H, Bae MJ, Yun EH, et al. Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. PLoS One 2013;8:e63439.
123. Lee DH, Ha MH, Christiani DC. Body weight, alcohol consumption and liver enzyme activity-a 4-year follow-up study. Int J Epidemiol 2001;30:766-70.
124. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007;32:453-68.
125. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004;34:9-19.
126. Tappy L, Lê KA. Does fructose consumption contribute to non-alcoholic fatty liver disease?. Clin Res Hepatol Gastroenterol 2012;36:554-60.
127. Lustig RH, Schmidt LA, Brindis CD. Public health: The toxic truth about sugar. Nature 2012;482:27-9.
128. Nomura K, Yamanouchi T. The role of fructoseenriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012;23:203-8.
129. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013;57:2525-31.
130. Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013;19:1166-72.
131. Neuschwander-Tetri BA. Carbohydrate intake and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2013;16:446-52.
132. Coss-Bu JA, Sunehag AL, Haymond MW. Contribution of galactose and fructose to glucose homeostasis. Metabolism 2009;58:1050-8.
133. Stanhope KL, Schwarz JM, Havel PJ. Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol 2013;24:198-206.
134. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
135. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
136. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
137. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
138. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver:significance of the liver-kidney contrast. Tohoku J Exp Med 1983;139:43-50.
139. Siest G, Schiele F, Galteau MM, Panek E, Steinmetz J, Fagnani F, et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975;21:1077-87.
140. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-9.
141. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006;101:76-82.
142. Zamin JI, de Mattos AA, Perin C, Ramos GZ. [The importance of AST / ALT rate in nonalcoholic steatohepatitis diagnosis]. Arq Gastroenterol 2002;39:22-6.
143. Nanji AA, French SW, Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986;36:266-9.
144. Pratt DS, Kaplan MM. Evaluation of abnormal liverenzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
145. Josekutty J, Iqbal J, Iwawaki T, Kohno K, Hussain MM. Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire1α/cJun to enhance plasma ALT/AST. J Biol Chem 2013;288:14372-83.
146. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-8.
147. Kawamoto R, Kohara K, Kusunoki T, Tabara Y, Abe M, Miki T. Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol 2012;11:117.
148. Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J Gastroenterol 2012;18:3775-81.
149. Khedmat H, Fallahian F, Abolghasemi H, Hajibeigi B, Attarchi Z, Alaeddini F, et al. Serum γ-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men. World J Gastroenterol 2007;13:889-94.
150. Hsu CH, Wang JY, Chen YL, Liu CC, Chang YL, Chen HS, et al. Relationships between alanine aminotransferase levels, abnormal liver echogenicity, and metabolic syndrome. J Am Board Fam Med 2011;24:407-14.
151. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935-44.
152. Uslusoy HS, Nak SG, Gülten M, Bi{dotless}yi{dotless}kli{dotless} Z. Nonalcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009;15:1863-8.
153. Mardini H, Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?. Ann Clin Biochem 2005;42:441-7.
154. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68.
155. Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 2008;47:569-75.
156. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-22.
157. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24.
158. Brucknerová I, Benedeková M, Holomán K, Bieliková E, Kostrová A, Ujházy E, et al. Delivery as "physiological stress" and its influence on liver enzymatic systems in asphyxial newborns. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:409-11.
159. Rosenthal P, Haight M. Aminotransferase as a prognostic index in infants with liver disease. Clin Chem 1990;36:346-8.
160. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
161. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006;26:1095-9.
162. Mera JR, Dickson B, Feldman M. Influence of gender on the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) in patients with and without hyperbilirubinemia. Dig Dis Sci 2008;53:799-802.
163. Lazo M, Selvin E, Clark JM. Brief communication:clinical implications of short-term variability in liver function test results. Ann Intern Med 2008;148:348-52.
164. Schmidt E, Schmidt FW, Chemnitz G, Kubale R, Lobers J. The Szasz-ratio (CK/GOT) as example for the diagnostic significance of enzyme ratios in serum. Klin Wochenschr 1980;58:709-18.
165. Dufour DR. Is it necessary to order aspartate aminotransferase with alanine aminotransferase in clinical practice? Author's Reply. Clin Chem 2001;47:1134-5.